Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ESH MM 2018 | Plasma cell leukemia and extramedullary disease in multiple myeloma

Niels van de Donk • 5 Oct 2018
ESH MM 2018
Multiple Myeloma

What is the current treatment landscape for plasma cell leukemia and extramedullary disease in multiple myeloma (MM)? We spoke to Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, about this at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

More from Niels van de Donk

Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Ajai Chari et al. • 4 Nov 2024
Advancements in quadruplet regimens for the treatment of multiple myeloma 2:17
Advancements in quadruplet regimens for the treatment of multiple myeloma
Niels van de Donk • 6 Jun 2024
Results of the first SRI of MajesTEC-7: safety of tec-DR in transplant-ineligible newly diagnosed MM 2:25
Results of the first SRI of MajesTEC-7: safety of tec-DR in transplant-ineligible newly diagnosed MM
Niels van de Donk • 6 Jun 2024
The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates) 2:16
The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates)
Niels van de Donk • 6 Jun 2024

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals